Atypical Antipsychotics in Primary Generalized Anxiety Disorder or Comorbid with Mood Disorders

Overview

Journal Expert Rev Neurother

Specialties Neurology
Pharmacology

Date 2009 Aug 14

PMID 19673604

Citations 14

Authors

Keming Gao

David V Sheehan

Joseph R Calabrese

Affiliations

Soon will be listed here.

Abstract

Generalized anxiety disorder (GAD) is a chronic, highly prevalent and debilitating disorder that commonly co-occurrs with mood disorders. Current available agents for GAD are limited either by their slow onsets of actions, unsatisfactory anxiolytic effects or potential for abuse/dependence. Atypical antipsychotics have been studied as alternatives. Olanzapine, risperidone and quetiapine immediate release have been explored in the treatment of refractory GAD and risperidone in bipolar anxiety with randomized, double-blind, placebo-controlled trials, but the results were not consistent. By contrast, quetiapine extended release (quetiapine-XR) 150 mg/day monotherapy yielded consistent anxiolytic effects across three studies that were superior to placebo and as effective as paroxetine 20 mg/day and escitalopram 10 mg/day but with an earlier onset of action. In a 52-week treatment of GAD, quetiapine-XR was superior to placebo in the prevention of anxiety relapses. Overall, atypical antipsychotics were relatively well tolerated, with common side effects of somnolence and sedation. However, in contrast to antidepressants and benzodiazepines, the long-term risk and benefit of atypical antipsychotics in the treatment of GAD is yet to be determined.

Citing Articles

extract alleviates quetiapine-induced sexual toxicity in male albino rats: Insights from UPLC-MS/MS metabolite profiling, structural and PI3K/NF-κB pathway assessments.

Yousof S, Shehata S, Ismail E, Abd El-Moneam S, Mansour B, Farag M Heliyon. 2024; 10(13):e33993.

PMID: 39071580 PMC: 11280294. DOI: 10.1016/j.heliyon.2024.e33993.

Olanzapine Effects on Parvalbumin/GAD67 Cell Numbers in Layers/Subregions of Dorsal Hippocampus of Chronically Socially Isolated Rats.

Stanisavljevic Ilic A, dordevic S, Inta D, Borgwardt S, Filipovic D Int J Mol Sci. 2023; 24(24).

PMID: 38139008 PMC: 10743576. DOI: 10.3390/ijms242417181.

Patterns of suboptimal antipsychotic use and misuse in Australia: What can routinely collected data tell us?.

Brett J, Gillies M, Buckley N, Pearson S, Zoega H Br J Clin Pharmacol. 2023; 89(11):3411-3420.

PMID: 37309058 PMC: 10953398. DOI: 10.1111/bcp.15821.

Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance.

Melaragno A Focus (Am Psychiatr Publ). 2021; 19(2):145-160.

PMID: 34690578 PMC: 8475920. DOI: 10.1176/appi.focus.20200048.

Comorbidity of bipolar and anxiety disorders: An overview of trends in research.

Spoorthy M, Chakrabarti S, Grover S World J Psychiatry. 2019; 9(1):7-29.

PMID: 30631749 PMC: 6323556. DOI: 10.5498/wjp.v9.i1.7.

References

Pandina G, Canuso C, Turkoz I, Kujawa M, Mahmoud R . Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull. 2007; 40(3):41-57. View

Brawman-Mintzer O, Knapp R, Nietert P . Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005; 66(10):1321-5. DOI: 10.4088/jcp.v66n1016. View

Gao K, Tolliver B, Kemp D, Verduin M, Ganocy S, Bilali S . Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder. J Affect Disord. 2008; 110(1-2):167-73. PMC: 2561239. DOI: 10.1016/j.jad.2007.12.229. View

Kessler R, DuPont R, Berglund P, Wittchen H . Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry. 1999; 156(12):1915-23. DOI: 10.1176/ajp.156.12.1915. View

Merikangas K, Akiskal H, Angst J, Greenberg P, Hirschfeld R, Petukhova M . Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007; 64(5):543-52. PMC: 1931566. DOI: 10.1001/archpsyc.64.5.543. View

Beasley Jr C, Potvin J . Fluoxetine: activating and sedating effects. Int Clin Psychopharmacol. 1993; 8(4):271-5. View

Tohen M, Vieta E, Calabrese J, Ketter T, Sachs G, Bowden C . Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003; 60(11):1079-88. DOI: 10.1001/archpsyc.60.11.1079. View

Fava M, Alpert J, Carmin C, Wisniewski S, Trivedi M, Biggs M . Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 2005; 34(7):1299-308. DOI: 10.1017/s0033291704002612. View

Lecrubier Y . Widespread underrecognition and undertreatment of anxiety and mood disorders: results from 3 European studies. J Clin Psychiatry. 2007; 68 Suppl 2:36-41. View

10.

Rollman B, Belnap B, Mazumdar S, Zhu F, Kroenke K, Schulberg H . Symptomatic severity of PRIME-MD diagnosed episodes of panic and generalized anxiety disorder in primary care. J Gen Intern Med. 2005; 20(7):623-8. PMC: 1490149. DOI: 10.1111/j.1525-1497.2005.0120.x. View

11.

Gelenberg A, Lydiard R, Rudolph R, Aguiar L, Haskins J, Salinas E . Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000; 283(23):3082-8. DOI: 10.1001/jama.283.23.3082. View

12.

Fava M, Rush A, Alpert J, Balasubramani G, Wisniewski S, Carmin C . Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008; 165(3):342-51. DOI: 10.1176/appi.ajp.2007.06111868. View

13.

Ballenger J, Davidson J, Lecrubier Y, Nutt D, Borkovec T, Rickels K . Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001; 62 Suppl 11:53-8. View

14.

Simon N, Connor K, Lebeau R, Hoge E, Worthington 3rd J, Zhang W . Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008; 197(4):675-81. DOI: 10.1007/s00213-008-1087-x. View

15.

Pollack M, Simon N, Zalta A, Worthington J, Hoge E, Mick E . Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2005; 59(3):211-5. DOI: 10.1016/j.biopsych.2005.07.005. View

16.

Thase M, Jonas A, Khan A, Bowden C, Wu X, McQuade R . Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008; 28(1):13-20. DOI: 10.1097/jcp.0b013e3181618eb4. View

17.

Calabrese J, Keck Jr P, Macfadden W, Minkwitz M, Ketter T, Weisler R . A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162(7):1351-60. DOI: 10.1176/appi.ajp.162.7.1351. View

18.

Otto M, Simon N, Wisniewski S, Miklowitz D, Kogan J, Reilly-Harrington N . Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006; 189:20-5. DOI: 10.1192/bjp.bp.104.007773. View

19.

Rickels K, Rynn M . What is generalized anxiety disorder?. J Clin Psychiatry. 2001; 62 Suppl 11:4-12; discussion 13-4. View

20.

Goldstein B, Levitt A . Prevalence and correlates of bipolar I disorder among adults with primary youth-onset anxiety disorders. J Affect Disord. 2007; 103(1-3):187-95. PMC: 2206538. DOI: 10.1016/j.jad.2007.01.029. View